ChronoScale Corporation
CHRN
NASDAQ Global Market25.54
USD
+0.16
- -
ChronoScale Corporation
CHRN
(NASDAQ Global Market)
Recent
price
25.54
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Ekso Bionics Holdings, Inc. designs, develops, manufactures, and sells robotic exoskeletons and related rehabilitation and mobility solutions for medical, industrial, and research applications; the company operates through product platforms including EksoNR and EksoASPIRE exoskeletons for clinical rehabilitation, EksoGEAR and other enterprise devices for industrial applications, and companion software and services to support device use and outcomes; it also provides training, maintenance, consulting, and data analytics services to clinicians, researchers, and corporate customers across multiple geographies. Ekso Bionics focuses on neurorehabilitation and mobility assistance, leveraging proprietary hardware, software, AI-enabled control features, and integration capabilities with hospital networks and rehabilitation centers; its products are marketed to hospitals, rehab centers, clinics, long-term care facilities, and enterprise customers with emphasis on stroke, spinal cord injury, acquired brain injury, and other mobility impairment conditions. The company is headquartered in the United States and operates in North America, Europe, the Middle East, Asia, and other regions through direct sales and a global distributor network; it pursues strategic partnerships, licensing arrangements, and potential acquisitions to expand its technology ladder and geographic footprint; Ekso Bionics was founded in 2005 and maintains its primary corporate offices in California, with manufacturing and R&D activities in multiple locations as part of a broader international network. The company’s latest changes include ongoing efforts to rebrand and reorganize under a new corporate identity as ChronoScale Corporation following a strategic transaction, with CHRN to trade on the Nasdaq Capital Market subject to regulatory approval, and a planned fiscal year-end shift to May 31; contemporaneously, the firm pursues updated product roadmaps, expanded partnerships, and potential capital market listings to support its growth initiatives. In addition, the company has announced initiatives around AI-assisted control, integration into enterprise health ecosystems, and broadened collaboration with clinical partners to validate and scale its exoskeleton technologies across global markets. The company’s public disclosures indicate continued focus on expanding its rehabilitation and mobility solutions portfolio, advancing AI-enabled features, and strengthening distribution and service capabilities globally. ChronoScale’s prospective listing and related corporate actions are subject to regulatory approvals and market conditions, with the CHRN ticker representing the anticipated equity vehicle post-closing.
ChronoScale Appoints Raj Jegannathan as Chief Technology Officer and Lawrence Lam as Chief Product Officer to Accelerate Global AI Infrastructure Strategy
ChronoScale Appoints Cenly Chen as Chief Executive Officer to Lead Next Phase of AI Compute Growth